|
Session 105
Poster Abstracts
Antiretroviral Pharmacokinetics during Pregnancy
Monday, 1-4 pm
Room: Hall A |
624
 |
Steady State Pharmacokinetics and Safety of Atazanavir after Treatment with ATV 300 mg Once Daily/Ritonavir 100 mg Once Daily + ZDV/3TC during the Third Trimester in HIV+ Women
T Eley1, E Vandeloise2, M Child1, F Conradie3, C Zorrilla4, D Josipovic5, Y Wang1, R Yang6, D McGrath6, Richard Bertz*1, and The Atazanavir 182 Pregnancy Study Group
1Bristol-Myers Squibb R&D, Princeton, NJ, US; 2Bristol-Myers Squibb R&D, Braine-l`Alleud, Belgium; 3HIV Clinical Trials Unit, Westdene, South Africa; 4Univ of Puerto Rico Sch of Med, San Juan, US; 5Perinatal HIV Res Unit, Soweto, South Africa; and 6Bristol-Myers Squibb R&D, Wallingford, CT, US |
625
|
Atazanavir in Pregnancy: Influence on Neonatal Hyperbilirubinemia
Claudia Ferreira*1,2, C Floch-Tudal3, F Meier1, G Peytavin4, J Treluyer5, V Jullien5, C Lejeune3, and L Mandelbrot1,6
1Hosp Louis Mourier, Colombes, France; 2French Agency for AIDS Res, Paris, France; 3Hosp Louis Mourier, Colombes, France; 4Hosp Bichat-Claude Bernard, Paris, France; 5Hosp St Vincent de Paul, Paris, France; and 6Diderot Univ, Paris, France |
626
|
Population Pharmacokinetics of Emtricitabine in HIV-infected Pregnant Women and Their Neonates: Temaa ANRS 12109
Deborah Hirt*1,2, S Urien1,2, E Rey1,3, E Arrive4, D Avit5, G Gray6, E Nerrienet7, D Ekouevi5, F Dabis4, and J M Treluyer1,2
1Hosp Cochin, Paris, France; 2Univ Paris Descartes, France; 3Univ Paris Descartes, France; 4INSERM U593, Inst for Publ Hlth, Epi and Devt, Univ Victor Segalen, Bordeaux, France; 5Prgm PACCI, Abidjan Côte d`Ivoire; 6Univ of the Witwatersrand, Soweto, South Africa; and 7Inst Pasteur, Phnom Penh, Cambodia |
627a
|
Safety and Efficacy of Tenofovir in Pregnant Women
Annette Haberl*1, R Linde1, A Reitter1, P Gute2, G Knecht2, M Mosch3, T Lennemann1, G Nisius1, C Stephan1, and S Staszewski1
1Hosp of JW Goethe Univ, Frankfurt, Germany; 2Infektiologikum, Frankfurt, Germany; and 3Medical Practice, Frankfurt, Germany |
627b
|
Use of Enfuvirtide in HIV+ Pregnant Women
Annette Haberl*1, R Linde1, A Reitter1, C Konigs1, G Nisius1, P Khaykin1, G Knecht2, H Stocker3, H W Doerr1, and S Staszewski1
1Hosp of JW Goethe Univ, Frankfurt, Germany; 2Infektiologikum, Frankfurt, Germany; and 3Therapia, Berlin, Germany |
| 628 |
Lopinavir Population Pharmacokinetics on HIV-infected Pregnant Women
Marion Bouillon Pichault*1, V Jullien1,2, E Azria1,2, E Panier1,2, G Firtion2, A Krivine1,2, A Compagnucci2, O Taulera2, O Launay1,2, J M Treluyer1,2, and EA 3620
1Univ Paris Descartes, France and 2Hosp Cochin, Paris, France |
629
|
High-dose Lopinavir and Standard-dose Emtricitabine Pharmacokinetics during Pregnancy and Postpartum
Brookie Best*1, A Stek2, C Hu3, S Burchett4, S Rossi1, E Smith5, B Sheeran6, J Read7, E Capparelli1, M Mirochnick8, and for the PACTG/IMPAACT P1026s Team
1Univ of California, San Diego, US; 2Univ of Southern California, Los Angeles, US; 3Harvard Sch of Publ Hlth, Boston, MA, US; 4Children`s Hosp Boston, MA, US; 5NIAID, NIH, Bethesda, MD, US; 6Social & Sci Systems, Silver Spring, MD, US; 7Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, US; and 8Boston Univ, MA, US |
630
|
Early Postpartum Pharmacokinetics of Lopinavir when Initiated Intrapartum in Thai Women: A Substudy of the IMPAACT P1032 Trial
Tim Cressey*1,2, R Van Dyke3, G Jourdain1,2, T Puthanakit4, A Roongpisuthipong5, J Achalapong6, P Yuthavisuthi7, S Prommas8, N Chotivanich9, M Mirochnick10, and IMPAACT P1032 Team
1Harvard Sch of Publ Hlth, Boston, MA, US; 2Chiang Mai Univ, Thailand; 3Tulane Univ, New Orleans, LA, US; 4Chiang Mai Univ, Thailand; 5Siriraj Hosp, Bangkok, Thailand; 6Chiang Rai Prachanukoh Hosp, Thailand; 7Prapokklao Hosp, Chantaburi, Thailand; 8Bhumibol Adulyadej Hosp, Bangkok, Thailand; 9Chonburi Hosp, Thailand; and 10Boston Univ Sch of Med, MA, US |
|
